Clinical Trials Logo

Filter by:
NCT ID: NCT05327907 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma

Start date: November 22, 2020
Phase:
Study type: Observational

The purpose of this study is to develop and validate a radiological nomogram including radiological characteristics, clinical risk factors, and medical history. And we aim to establish a noninvasive method for the diagnosis of intrahepatic cholangiocarcinoma (ICC), and to construct a differential diagnosis model for ICC and hepatocellular carcinoma (HCC) with higher sensitivity and accuracy.

NCT ID: NCT05327621 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of a PARP inhibitor, Pamiparib, in metastatic castration-resistant prostate cancer patients with homologous recombination deficiency or BRCA 1 or 2 somatic/germline mutation.

NCT ID: NCT05327582 Recruiting - Pancreatic Cancer Clinical Trials

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Start date: April 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Immunotherapy of cancer based on PD-1/PD-L1 blockade has prompted a revolution in cancer clinical management, albeit as yet immunotherapy-based treatment approaches in pancreatic cancer and biliary tract cancer (BTC) remain to have proven value, highlights the urgency for designing novel therapeutic strategies to combat these deadly diseases. The immunomodulatory effect of lenvatinib (Lenvatinib is an oral multi-kinase inhibitor) on tumor microenvironments may contribute to antitumor activity of immune checkpoint blockade. This one-arm, phase I/II study is designed to assess the safety and efficacy of the combined regimen of Durvalumab (anti-PD-L1 antibody), Lenvatinib and Paclitaxel albumin (nab-paclitaxel).

NCT ID: NCT05327517 Recruiting - Clinical trials for Cervical Esophageal Cancer

Surgery or Chemoradiotherapy for Cervical Esophageal Cancer

Start date: April 10, 2022
Phase: N/A
Study type: Interventional

To compare surgery with definitive chemoradiotherapy for patients with resectable cervical esophageal squamous cell carcinoma.

NCT ID: NCT05327413 Recruiting - Knee Osteoarthritis Clinical Trials

Femoral External Rotation Measured on CT and MRI

Start date: April 1, 2022
Phase:
Study type: Observational

This study aims to compare the femoral external rotation measured on CT and MRI to that measured intraoperatively to clarify the influence of residual cartilage on posterior condyle on the preoperative planning of total knee arthroplasty.

NCT ID: NCT05327400 Recruiting - Gene Expression Clinical Trials

Expression and Clinical Significance of IGHD in Pancreatic Cancer

Start date: May 1, 2022
Phase:
Study type: Observational [Patient Registry]

Background : Pancreatic cancer is the most malignant tumor in the digestive system, with low level of early diagnosis and poor prognosis. There is a lack of high sensitive and specific molecular markers in the diagnosis, treatment and prognosis of pancreatic cancer. Objective: To explore the expression of IGHD in pancreatic cancer and its correlation with clinical parameters, and to explore its prognostic value in patients with pancreatic cancer. Methods: In this study, qRT-PCR was used to detect IGHD expression in peripheral blood. The expression of IGHD in pancreatic cancer and healthy individuals was compared. The PCR results were combined with clinical data of patients. To compare the expression of IGHD in different pancreatic cancer stages and evaluate whether IGHD expression in peripheral blood can be a potential biomarker for the diagnosis of pancreatic cancer, chi-square test was used to analyze the factors influencing the expression level of IGHD. Kaplan-Meier was used to analyze patient prognosis, and further Cox regression analysis was used to analyze the factors influencing patient prognosis and independent risk factors.

NCT ID: NCT05327114 Recruiting - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start date: September 23, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

NCT ID: NCT05327036 Recruiting - Clinical trials for Umbilical Artery Embolism,Single Umbilical Artery,Pregnancy Outcome

The Effect of Single Umbilical Artery Caused by Umbilical Artery Embolism on Pregnancy Outcome

Start date: January 1, 2022
Phase:
Study type: Observational

To investigate the relationship between single umbilical artery caused by umbilical artery embolism and pregnancy outcome , and to provide evidence-based evidence for peripartum health care of pregnant women with umbilical artery embolism.

NCT ID: NCT05326932 Recruiting - Clinical trials for Acute Ischemic Stroke

Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial

LATE-MT
Start date: November 3, 2022
Phase: N/A
Study type: Interventional

A multi-center, prospective, randomized, open-label, adaptive group sequential designed, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS

NCT ID: NCT05326672 Recruiting - Atopic Dermatitis Clinical Trials

Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis

Start date: April 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multicenter, placebo-controlled clinical Phase III study to evaluate the safety and efficacy of Benvitimod cream, 1% twice daily for the treatment of mild to moderate atopic dermatitis. Approximately 240 participants with mild to moderate atopic dermatitis will be enrolled and randomly divided into two groups in a 2:1 ratio. They will use either the Benvitimod cream or placebo at the skin with atopic dermatitis for 8 weeks.